The worldwide personalized antigen malignancy therapeutic industry is currently experiencing a turbulent period of advancement, fueled by remarkable progress in immunogenomics and a growing awareness of the immune system's role in combating cancers. Forecasts indicate a sustained rise in the next years, driven by experimental assessments demonstrat